OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells , or tumor-initiating cells, today announced clinical progress with its Anti-Notch2/3 product candidate, which will trigger an $8 million milestone payment from the company's strategic collaborator GlaxoSmithKline .
's stock had its "buy" rating reiterated by equities research analysts at TheStreet in a research note issued to investors on Tuesday, AnalystRatingsNetwork reports.
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! DUBLIN, Ireland, 13th May 2013: Genable Technologies Ltd., a bio-pharmaceutical company developing new gene medicines to treat 'dominant' genetic diseases, today announced the appointment of Annette Clancy as Chairman of the Board.
U.S. stocks closed little changed on Monday, pausing after hitting record highs last week, but strength in health care issues helped to keep declines in check.
The FTSE 100 set a five-and-a-half-year record of 6,638 points last Friday, and though the index is down from that today at 6,617, it still looks like hanging on to the 6,600 level -- even if that absolute value is ultimately meaningless.
's stock had its "buy" rating reiterated by investment analysts at Citigroup in a note issued to investors on Monday, ARN reports.
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! LONDON, UK, 13 May, 2013 - Skyepharma PLC , the expert oral and inhalation drug delivery company, announces that the United States Food and Drug Administration has approved the New Drug Application for BREOa ELLIPTAa , a combination product submitted by ... (more)
U.K. stocks managed to eke out an eighth straight day of gains on Monday, as Royal Dutch Shell PLC rose after announcing a share buyback and GlaxoSmithKline PLC climbed after a new drug approval.
Elan Corp. agreed to pay $1 billion for a share of the royalties on new drugs from Theravance Inc.
Elan will make a once off payment of $1 billion to the company in exchange for a 21% stake in future royalty payments from four respiratory programmes which Theravance has developed with GlaxosmithKline.
Save the Children, in its State of the World's Mothers report this week, identified this intervention as a key strategy to saving as many as one million babies worldwide who die each year on their first day of life.
GlaxoSmithKline plc and Theravance, Inc. today announced that the US Food and Drug Administration has approved BREO ELLIPTA as an inhaled long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease , including chronic bronchitis and/or emphysema.
One of Vancouver's two inimitable "Hobbit Houses" is on the market for an asking price of $2.86 million.